Merck management commentary: New products drive 5% revenue growth in Q3 2026
Bitget2026/10/29 10:45- Merck's management commentary attributed third-quarter 2026 revenue growth of 5% to $18.1 billion to new products, oncology and animal health.
- Keytruda-family sales rose 6% excluding currency effects to $8.6 billion, driven by earlier-stage cancer uptake and metastatic demand.
- Non-GAAP operating expenses increased 12% to $7.4 billion, reflecting launch investments, pipeline spending and a licensing charge.
- Full-year revenue guidance narrowed to $66.8 billion–$67.3 billion; non-GAAP EPS guidance narrowed to $2.77–$2.82, with both midpoints raised.
- Favorable U.S. purchase timing boosted quarterly sales by approximately $550 million; Keytruda and Winrevair benefits are expected to reverse in the fourth quarter.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After the sharp decline in tech stocks, the White House suddenly canceled the top tech advisor meeting the following day.
The White House has canceled the previously scheduled President’s Council of Advisors on Science and Technology meeting, which was set for Friday and includes prominent tech leaders such as Nvidia CEO Jensen Huang and Meta CEO Mark Zuckerberg. The Department of Energy's meeting page briefly listed November 13 as the new meeting date, but the agency later sent an email retracting this information. Currently, the specific date for rescheduling the meeting remains unclear.
Turtle Creek Asset Management Reports Sale of $347,850 in Jeld-Wen Common Shares
GLOBALFOUNDRIES Director Ganesh Moorthy Reports $93,687.50 Share Acquisition
Crypto prices
More
